Prostate Cancer - Results from #1060

Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes. April 22, 2024

The Future State of Race/Ethnicity in Urology: Urology Workforce Projection From 2021-2061 April 19, 2024

Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models. April 19, 2024

BET inhibitors as a therapeutic intervention in gastrointestinal gene signature-positive castration-resistant prostate cancer. April 19, 2024

Ketogenic diet alters the epigenetic and immune landscape of prostate cancer to overcome resistance to immune checkpoint blockade therapy. April 19, 2024

Patient-centred pathology reporting improves patient experience and understanding of disease in prostate cancer care. April 19, 2024

Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer. April 19, 2024

Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. April 19, 2024

The impact of pre-biopsy MRI and additional testing on prostate cancer screening outcomes: A rapid review. April 19, 2024

Health-related quality of life following salvage radical prostatectomy for recurrent prostate cancer after radiotherapy or focal therapy. April 19, 2024

Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer April 18, 2024

Unlocking ferroptosis in prostate cancer - the road to novel therapies and imaging markers. April 18, 2024

Population-based study of disease trajectory after radical treatment for high-risk prostate cancer. April 18, 2024

Prognostic impact of prostate-specific membrane antigen positron emission tomography (PSMA PET) staging for clinically node-positive prostate cancer. April 18, 2024

Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cance April 18, 2024

Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome. April 18, 2024

Management of advanced prostate cancer in the Asia-Pacific region: Summary of the Asia-Pacific Advanced Prostate Cancer Consensus Conference 2023. April 18, 2024

Timing of treatment shapes the path to androgen receptor signaling inhibitor resistance in prostate cancer. April 18, 2024

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer. April 18, 2024

Redirecting the pioneering function of FOXA1 with covalent small molecules. April 18, 2024

Page 54 of 1437